Article
The Food and Drug Administration said its authority over compounding pharmacies is limited and needs to be strengthened in the wake of a multistate meningitis outbreak caused by tainted steroid injections produced by a pharmacy in Massachusetts.
The FDA has come under scrutiny for its oversight of the New England Compounding Center, the Framingham, Mass.-based compounding pharmacy that is responsible for distributing contaminated vials of preservative-free methylprednisolone acetate.
Read the full story:http://bit.ly/XF0gF0
Source: ModernHealthcare.com
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831
© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.